Actively Recruiting
High Definition Medicine for Solid Tumors Oncology
Led by Centro Nacional de Investigaciones Oncologicas CARLOS III · Updated on 2024-09-19
300
Participants Needed
9
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The present study aims to analyze different genetic, phenotypic, environmental, social and lifestyle characteristics of cancer patients who are going to start a first line of cancer treatment with palliative intent and their possible relationship with tumor response or tolerance to treatment. In this way, the aim is to identify a series of variables that allow a better selection of patients and oncological treatments.
CONDITIONS
Official Title
High Definition Medicine for Solid Tumors Oncology
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of solid tumor cancer, starting first-line treatment for metastatic disease
- Advanced tumor stage III or IV, not eligible for curative treatment
- Preference for women with hormone-positive, HER2-negative breast cancer receiving CDK4/6 inhibitor plus hormone therapy
- Women with lung or colon cancer of any subtype starting first-line treatment
- Patients starting known treatments within clinical trials (excluding double-blind studies)
- ECOG performance status less than 2
- Ability to carry and use the wearable device
- Access to a mobile device with internet and email
- Ability to complete quality of life, nutrition, and mental health questionnaires
- Provided written informed consent before screening
- Patients with co-morbidities included
- Pregnant women included
You will not qualify if you...
- Previously received cancer treatment for metastatic disease or with palliative intent
- Planned participation in double-blind treatment trials
- Other active malignant diseases that could affect study compliance or results, except treated basal cell carcinoma or cervical cancer in situ
- Concurrent illnesses that significantly interfere with participation, as judged by the investigator
- Use of implanted therapeutic electronic devices like pacemakers, defibrillators, or cardiac resynchronizers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Hospital Universitario A Coruña
A Coruña, A Coruña/ Galicia, Spain, 15006
Actively Recruiting
2
Hospital Universitario de Fuenlabrada
Fuenlabrada, Madrid, Spain, 28942
Actively Recruiting
3
Hospital Son Espases
Palma de Mallorca, Mallorca / Baleares, Spain, 07120
Actively Recruiting
4
Complejo Hospitalario de Navarra
Pamplona, Navarre, Spain, 31008
Actively Recruiting
5
Hospital Virgen de la Macarena
Seville, Sevilla/ Andalucia, Spain, 41009
Actively Recruiting
6
ICO Hospitalet Bellvitge
Barcelona, Spain, 08908
Actively Recruiting
7
Hospital San Pedro Alcántara de Cáceres
Cáceres, Spain, 10003
Actively Recruiting
8
Hospital de La Princesa
Madrid, Spain, 28006
Actively Recruiting
9
Hospital General de Valencia
Valencia, Spain, 46014
Actively Recruiting
Research Team
M
Miguel A Quintela, PhD
CONTACT
B
Berta Nasarre, Pharmacist
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here